Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chen, Yeu-Chin
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	Active, not recruiting	3	500	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa	Loxo Oncology, Inc., Eli Lilly and Company	Lymphoma, Mantle-Cell	12/25	07/26
NCT05981274: A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)	Recruiting	N/A	45	RoW	serum biomarker.	Tri-Service General Hospital	Severe Hemophilia A Without Inhibitor	12/27	12/27
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A	Active, not recruiting	N/A	207	Europe, US, RoW	ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855	Baxalta now part of Shire	Hemophilia A	02/30	02/30